High failure rates in clinical trials for head and neck squamous cell carcinoma (HNSCC) have raised concerns in the medical community. Many trials are terminated before completion, often without delivering potential treatments that could help patients. Understanding the reasons for these failures is crucial, especially as new therapies emerge and the landscape of cancer treatment evolves.

Why it matters

The implications of trial failures go beyond just lost resources; they affect the availability of innovative therapies for patients battling head and neck cancers. When trials fail to produce results, it creates uncertainty in clinical practice, making it more challenging for healthcare professionals to guide patients through the next steps. This situation underscores the need for better-designed trials that can successfully navigate through various hurdles, such as recruitment issues and strategic decisions made by sponsors.

What the research says

Due to the high failure rates of HNSCC clinical trials, researchers set out to discover the characteristics that were associated with the failures. The authors defined the “trial failures” as either termination or withdrawal in clinical trials. Researchers used clinicaltrials.gov and identified HNSCC clinical trials from January 2000 to December 2024. Temporal analysis illustrated a steadily growing rate of the clinical trials since as early as the year 2000.

Theprimary outcome of this study was trial failure and the association between the clinical trial characteristics (i.e., phase, enrollment, funding source, intervention type, and age-eligibility criteria).

A total of 692 clinical trials were analyzed, and 346 trials were identified as trial failures, while the remaining 346 trials were completed control trials.

Top Reasons for Failure	Number of Trials, Overall Percentage
Strategic decisions (defined as non-scientific, sponsor-driven choices)	102 trials, 29.5%
Poor recruitment	90 trials, 26.0%

Strategic Decisions

Researchers explain that the strategic decisions made that caused 102/346 trials to fail were predominantly in phase 1 trials, industry-sponsored trials, and immunotherapy and target therapy trials.

The National Institutes of Health (NIH) reports three general rationales for early termination of clinical trials: futility, safety, and efficacy.

Terminating for futility is determined by a trial’s unlikelihood to attain its scientific objective. By terminating a trial due to futility, researchers, sponsors, and patients alike minimize the unnecessary burden on those involved as well as prevent unnecessary use of resources.
Terminating for safety typically applies when interim data shows that the harm of the treatment in question clearly outweighs the potential benefits. However, researchers may run into issues due to safety-related data not being available in real time. Depending on the type of harm a potential treatment can inflict, a data and safety monitoring board (DSMB) may be incorporated into the trial design.
Terminating for efficacy generally occurs when interim data suggest that the treatment being tested is more efficacious than its comparator.

Poor Recruitment

The second top reason for trial failure was identified as poor recruitment, with 90 trials (26.0%) identified. The data showed that poor recruitment as a reason for failure was more commonly found in later-phase trials, non-industry-sponsored trials, and trials that investigated chemotherapy, radiation, chemoradiation, combination treatments, and supportive care.

While it is known that clinical trials play a crucial role in advancing scientific innovation and providing evidence of newer therapies, ensuring active and appropriate participants is an uphill battle. Certain populations continue to face underrepresentation and are constantly navigating intersecting barriers like race, ethnicity, socioeconomic status, language, and access to healthcare. Commonly cited barriers specifically include restrictive criteria, mistrust of the medical system, and limited trial site access.

To combat these barriers, agencies that sponsor clinical trials, like the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC), have developed many policies and guidelines aimed at diversifying clinical trial participants and helping bridge the gap in demographics that are historically underrepresented. However, these policies fail to present a detailed plan on how to recruit a diverse cohort.

Additional reasons for poor recruitment include:

Little to no support and coordination from leadership regarding efforts to recruit and retain minorities
Limited staff/staff shortages lead to missed opportunities to connect with participants who later drop off
Administrative burden
Lack of resources for recruitment and retention

Who it affects

Patients diagnosed with head and neck cancers are directly impacted by the high rate of terminated trials, as these failures can delay access to breakthrough treatments. Clinicians and researchers, including surgical oncologists and other specialists involved in cancer care, also feel the effects, as they rely on robust clinical data to provide the best possible care. Additionally, healthcare systems struggle with the challenge of integrating new therapies, prolonging the journey towards effective treatment solutions.

What is Head and Neck Squamous Cell Carcinoma (HNSCC)?

Head and neck squamous cell carcinoma (HNSCC) isa group of cancers that involve the oral cavity, pharynx, hypopharynx, larynx, nasal cavity, and salivary glands. Together, these cancers make HNSCC the seventh most common cancer diagnosis worldwide. Specific demographics are particularly susceptible to HNSCC, with higher rates observed among men, older adults, and individuals of lower socioeconomic status. Additionally,well-established risk factors for developing HNSCC include smoking tobacco and consuming alcohol, as well as emerging factors such as viral infections, including human papillomavirus (HPV) and Epstein–Barr virus (EBV) infections.

According to the National Cancer Institute (NCI), these cancers arenearly twice as commonamong men (17.4 per 100,000 people) as they are among women (6.6 per 100,000).

Using Real-World Data (RWD) and Implementation Science

To assist with the future of clinical trials in HNSCC, trial sponsors can utilize real-world data and implementation science to create protocols and study designs that are better equipped to deal with possible strategic decisions at play and bolster poor recruitment. For example, implementation science strategies have studied the use of healthcare innovations like electronic health records (EHRs), cancer centers, and telehealth in the successful and sustainable implementation of systems for the recruitment and retention of underrepresented populations in cancer clinical trials.

By understanding termination factors of clinical trials in HNSCC research, researchers, trial sponsors, and participants can work together to drive more trials to completion.

What changes

Efforts should be made to simplify trial eligibility criteria to enhance recruitment and increase the likelihood of bringing valuable therapies to patients.
Collaboration among healthcare professionals, including better input from multidisciplinary teams, can lead to more effective trial designs and higher chances of success.
Incorporating safeguards such as improved data monitoring and site selection can help minimize operational failures in clinical trials.
Anticipating challenges of possible strategic decisions and poor recruitment concerns may aid in proactive problem-solving.

References

https://pubmed.ncbi.nlm.nih.gov/41481330/
https://rethinkingclinicaltrials.org/chapters/ethics-and-regulatory/data-and-safety-monitoring/decisions-about-early-termination/
https://www.nidcr.nih.gov/research/conducting-nidcr-clinical-research/data-and-safety-monitoring-board-guidelines
https://pmc.ncbi.nlm.nih.gov/articles/PMC11537200/
https://pmc.ncbi.nlm.nih.gov/articles/PMC10304137/
https://seer.cancer.gov/statistics-network/explorer/application.html?site=3&data\_type=1&graph\_type=10&compareBy=sex&chk\_sex\_1=1&chk\_sex\_3=3&chk\_sex\_2=2&series=9&race=1&age\_range=1&stage=101&advopt\_precision=1&advopt\_show\_ci=on#resultsRegion0

ShareFacebook

One story a day